ArticleACS biomaterials science & engineering2018
Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy.
Article in ACS biomaterials science & engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Pro-Apoptotic Organometallic Sn(IV) Bis-Organosilane Benzoate Complexes with Sustained Reduction in Cell Viability Under Resistance-like Conditions in Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
- Gold- and Platinum-Peptide Bioconjugates in Cancer Therapy: Recent Advances and Future Directions.Pharmaceutics · 2026Review
- Article
- Ergothioneine Attenuates Oxaliplatin-Induced Peripheral Neuropathy Without Compromising Antitumor Efficacy.International journal of molecular sciences · 2025Article
- Identification and validation of a novel risk model based on cuproptosis‑associated m6A for head and neck squamous cell carcinoma.BMC medical genomics · 2024Article
- PLA2G4A and ACHE modulate lipid profiles via glycerophospholipid metabolism in platinum-resistant gastric cancer.Journal of translational medicine · 2024Article
- Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance.RSC chemical biology · 2023Review
- H-Dot Mediated Nanotherapeutics Mitigate Systemic Toxicity of Platinum-Based Anticancer Drugs.International journal of molecular sciences · 2023Article
- Pt(II)-PLGA Hybrid in a pH-Responsive Nanoparticle System Targeting Ovarian Cancer.Pharmaceutics · 2023Article
- First-in-Class Dual Hybrid Carbonic Anhydrase Inhibitors and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced Neuropathy.Journal of medicinal chemistry · 2023Article
- Investigating the role of peptides in effective therapies against cancer.Cancer cell international · 2022Review
- Platinum-based drugs for cancer therapy and anti-tumor strategies.Theranostics · 2022Review
- Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy.Drug delivery · 2021Article
- A click-based modular approach to introduction of peroxides onto molecules and nanostructures.RSC advances · 2020Article
- Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhancedDrug delivery · 2020Article
- Recent advances in metallopolymer-based drug delivery systems.RSC advances · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Platinum therapy represents first line of treatment in many malignancies but its high systemic toxicity limits the therapeutic dosage. Herein, we report the synthesis of carboplatin-like complexes with azide and alkyne functional groups and the formation of a platinum (II) - nuclear localization sequence peptide (Pt-NLS) hybrid to improve the import of platinum (II) complexes directly into the cell's nucleus. The Pt-NLS hybrid successfully enters cells and their nuclei, forming Pt-induced nuclear lesions. The in vitro efficacy of Pt-NLS is high, superior to native carboplatin at the same concentration. The methodology used is simple and cost-effective and most importantly can easily be extended to load the Pt (II) onto other supports, opening new possibilities for enhanced delivery of Pt (II) therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.